12:00 AM
Mar 05, 2012
 |  BC Week In Review  |  Clinical News  |  Regulatory

Altoprev lovastatin XL regulatory update

FDA approved several label changes for the statin class of cholesterol drugs, including eliminating the need for routine periodic monitoring of liver enzymes. The labels now recommend that liver enzyme tests should be performed before starting statin therapy and as clinically indicated thereafter. The agency concluded that serious liver injury with statins is rare and unpredictable, and that routine monitoring of liver enzymes does not appear to be effective in detecting or preventing the side effect.

Additionally, the labels now include information about certain cognitive effects, including memory loss and confusion, and hyperglycemia that have been reported with statin use. FDA specifically updated...

Read the full 496 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >